San Diego—In hematologic malignancies, chimeric antigen receptor (CAR)-modified T cells will be increasingly combined with other therapeutic strategies, according to multiple studies presented at the 2018 annual meeting of the American Society of Hematology (ASH).
Of many studies at ASH suggesting benefit from combination treatment, one tested pretreatment with a targeted therapy, another evaluated the effect of boosting CAR T-cell response with a checkpoint inhibitor, and a third tested